A spectroscopic study on the coordination and solution structures of the interaction systems between biperoxidovanadate complexes and the pyrazolylpyridine-like ligands

Luminescence Color and Intensity Changes of Nitridorhenium(V) Complexes Induced by Protonation/Deprotonation on the Bidentate Azolylpyridine Ligands

Tricyanidonitridorhenium(V) complexes with azolylpyridines, namely, [ReN(CN)3(H-N2py)]- (1-H, H-N2py = 2-(3-pyrazolyl)pyridine) and [ReN(CN)3(L)]2- (2-a, L = 2-[1,2,3]-triazol-4-yl-pyridine anion (N3py-), and 3-a, that is, L = 2-(tetrazol-5-yl)-pyridine anion (N4py-)), were newly synthesized and characterized. The structures of the new complexes were determined by single-crystal X-ray analysis. The 1-H complex includes two geometrical isomers in which an isomer is the conformation with the pyridyl (py) and pyrazolyl (pyrz) moieties of H-N2py occupying the trans site to the nitrido (the ax site) and the trans site to the cyanido (the eq site), respectively, in a bidentate fashion; the other isomer is the py and pyrz moieties coordinated to the eq and ax sites. In 2-a and 3-a, the triazolyl (trz) and tetrazoly (tetrz) moieties in N3py- and N4py- occupy the eq site, and the py moieties in N3py- and N4py- coordinate to the ax site. The complex 1-H is deprotonated upon the addition of 1,8-diazabicyclo[5.4.0]undec-7-one or NaOH to produce [ReN(CN)3(N2py)]2- (1-a), and 2-a is protonated upon the addition of p-toluene sulfonic acid (TsOH) to give [ReN(CN)3(H-N3py)]- (2-H) in DMSO. The protonation reaction does not occur for 3-a with TsOH in DMSO. All the complexes show one-electron redox waves of the Re(VI)/Re(V) and azolylpyridine ligand-centered processes in 0.1 M (n-C4H9)4NPF6-DMSO. All the complexes exhibit photoluminescence in DMSO and in the crystalline phase at 296 K. The emissive excited states of the complexes in DMSO were assigned to MLCT with a spin triplet nature. The emission band shifts to shorter and longer wavelengths upon protonation and deprotonation of the coordinated azolylpyridines, respectively. The emission color and intensity changes of 2-H and 2-a in the presence of acidic and basic vapors were investigated.

Thermally Stable Fluorogenic Zn(II) Sensor Based on a Bis(benzimidazole)pyridine-Linked Phenyl-Silsesquioxane Polymer

A 2,6-bis(2-benzimidazolyl) pyridine-linked silsesquioxane-based semi-branched polymer was synthesized, and its photophysical and metal-sensing properties have been investigated. The polymer is thermally stable up to 285 °C and emits blue in both solid and solution state. The emission of the polymer is sensitive to pH and is gradually decreased and quenched upon protonation of the linkers. The initial emission color is recoverable upon deprotonation with triethylamine. The polymer also shows unique spectroscopic properties in both absorption and emission upon long-term UV irradiation, with red-shifted absorption and emission not present in a simple blended system of phenylsilsesquioxane and linker, suggesting that a long-lived energy transfer or charge separated state is present. In addition, the polymer acts as a fluorescence shift sensor for Zn(II) ions, with red shifts observed from 464 to 528 nm, and reversible binding by the introduction of a competitive ligand such as tetrahydrofuran. The ion sensing mechanism can differentiate Zn(II) from Cd(II) by fluorescence color shifts, which is unique because they are in the same group of the periodic table and possess similar chemical properties. Finally, the polymer system embedded in a paper strip acts as a fluorescent chemosensor for Zn(II) ions in solution, showing its potential as a solid phase ion extractor.

Bis-cyclometallated Ir(III) complexes containing 2-(1H-pyrazol-3-yl)pyridine ligands; influence of substituents and cyclometallating ligands on response to changes in pH

Bis-cyclometallated Ir(iii) complexes containing 2-(1H-pyrazol-3-yl)pyridine ligands have been synthesised. Their absorption is almost unchanged with changes in pH however the emission intensities vary by a factor of up to three and the complexes have emission pKas in the range 8.0 to 10.0. Substituents on the pyrazole have only a minor effect on the emission pKa. Surprisingly the complexes with phenylpyrazole cyclometallated ligands 3aL1-3 showed an intensity decrease with increasing pH (switch off) whilst the corresponding phenylpyridine ones 3cL1-3 showed an increase in emission intensity with increasing pH. Putting electron-withdrawing CF3 substituents on the cyclometallating phenyls reduced the pKa of the complexes to 6.8-7.8, thereby extending the useful pKa range; however, in general it tended to reduce the magnitude of the change in emission intensity. Surprisingly the CF3-substituted complexes also showed a complete reversal in the direction of the intensity change when compared to their respective unsubstituted congeners.

Vanadium and insulin: Partners in metabolic regulation

Since the 1970s, the biological role of vanadium compounds has been discussed as insulin-mimetic or insulin-enhancer agents. The action of vanadium compounds has been investigated to determine how they influence the insulin signaling pathway. Khan and coworkers proposed key proteins for the insulin pathway study, introducing the concept "critical nodes". In this review, we also considered critical kinases and phosphatases that participate in this pathway, which will permit a better comprehension of a critical node, where vanadium can act: a) insulin receptor, insulin receptor substrates, and protein tyrosine phosphatases; b) phosphatidylinositol 3'-kinase, 3-phosphoinositide-dependent protein kinase and mammalian target of rapamycin complex, protein kinase B, and phosphatase and tensin homolog; and c) insulin receptor substrates and mitogen-activated protein kinases, each node having specific negative modulators. Additionally, leptin signaling was considered because together with insulin, it modulates glucose and lipid homeostasis. Even in recent literature, the possibility of vanadium acting against metabolic diseases or cancer is confirmed although the mechanisms of action are not well understood because these critical nodes have not been systematically investigated. Through this review, we establish that vanadium compounds mainly act as phosphatase inhibitors and hypothesize on their capacity to affect kinases, which are critical to other hormones that also act on common parts of the insulin pathway.

Vanadium in Biological Action: Chemical, Pharmacological Aspects, and Metabolic Implications in Diabetes Mellitus

Vanadium compounds have been primarily investigated as potential therapeutic agents for the treatment of various major health issues, including cancer, atherosclerosis, and diabetes. The translation of vanadium-based compounds into clinical trials and ultimately into disease treatments remains hampered by the absence of a basic pharmacological and metabolic comprehension of such compounds. In this review, we examine the development of vanadium-containing compounds in biological systems regarding the role of the physiological environment, dosage, intracellular interactions, metabolic transformations, modulation of signaling pathways, toxicology, and transport and tissue distribution as well as therapeutic implications. From our point of view, the toxicological and pharmacological aspects in animal models and humans are not understood completely, and thus, we introduced them in a physiological environment and dosage context. Different transport proteins in blood plasma and mechanistic transport determinants are discussed. Furthermore, an overview of different vanadium species and the role of physiological factors (i.e., pH, redox conditions, concentration, and so on) are considered. Mechanistic specifications about different signaling pathways are discussed, particularly the phosphatases and kinases that are modulated dynamically by vanadium compounds because until now, the focus only has been on protein tyrosine phosphatase 1B as a vanadium target. Particular emphasis is laid on the therapeutic ability of vanadium-based compounds and their role for the treatment of diabetes mellitus, specifically on that of vanadate- and polioxovanadate-containing compounds. We aim at shedding light on the prevailing gaps between primary scientific data and information from animal models and human studies.